Birchview Fund

Monteris Medical, Inc. is a medical device company that specializes in developing and marketing technologies for minimally invasive neurosurgery, particularly focused on the treatment of brain lesions. The company's flagship product, the NeuroBlate System, is a laser thermotherapy system designed for the volumetric ablation of pathological brain lesions, including both primary and metastatic tumors. This system utilizes magnetic resonance imaging (MRI) guidance and applies focused laser energy to effectively target and ablate tumors while minimizing damage to surrounding healthy tissue. Monteris Medical also offers various stereotactic anchoring devices for precise image-guided trajectory alignment, as well as stabilization systems for MRI-based procedures that require head fixation. Founded in 1999 and headquartered in Plymouth, Minnesota, the company serves neurosurgeons across the United States through a dedicated sales force. Monteris Medical was previously known as AutoLITT until rebranding in 2003.

Ogee, Inc. is a luxury organic skincare brand based in Burlington, Vermont, that specializes in manufacturing and selling a range of skin care products, including lip care, moisturizers, serums, and cleansing products. Committed to organic and sustainable practices, Ogee emphasizes ethical sourcing and the use of high-quality natural ingredients, which are certified organic by NSF. The company integrates American-grown, cold-pressed jojoba oil with innovative skincare science to enhance the effectiveness of its products. Ogee markets its offerings through various retailers and online platforms, catering to consumers seeking skin-friendly and environmentally conscious beauty solutions. Founded in 2014, Ogee continues to uphold its dedication to quality and sustainability in the skincare industry.

Monteris Medical, Inc. is a medical device company that specializes in developing and marketing technologies for minimally invasive neurosurgery, particularly focused on the treatment of brain lesions. The company's flagship product, the NeuroBlate System, is a laser thermotherapy system designed for the volumetric ablation of pathological brain lesions, including both primary and metastatic tumors. This system utilizes magnetic resonance imaging (MRI) guidance and applies focused laser energy to effectively target and ablate tumors while minimizing damage to surrounding healthy tissue. Monteris Medical also offers various stereotactic anchoring devices for precise image-guided trajectory alignment, as well as stabilization systems for MRI-based procedures that require head fixation. Founded in 1999 and headquartered in Plymouth, Minnesota, the company serves neurosurgeons across the United States through a dedicated sales force. Monteris Medical was previously known as AutoLITT until rebranding in 2003.

ContraFect Corporation is a clinical-stage biotechnology firm based in Yonkers, New York, specializing in the development of therapeutic proteins and antibodies for the treatment of life-threatening, drug-resistant infectious diseases. The company's lead candidate, CF-301, is a novel lysin currently undergoing Phase III clinical trials for staphylococcus aureus bacteremia, including endocarditis. ContraFect is also advancing CF-296, an engineered lysin targeting invasive staphylococcal infections, and CF-370, an investigational therapy in preclinical stages aimed at treating infections caused by pseudomonas aeruginosa. The company has a research collaboration with The Rockefeller University to identify novel lysin candidates targeting gram-negative pathogens. Additionally, ContraFect has initiated an expanded access program for exebacase, intended for patients with persistent bacteremia linked to methicillin-resistant Staphylococcus aureus in COVID-19 cases. Founded in 2008, ContraFect aims to address the challenges posed by multi-drug resistant infections through its innovative treatments.

Aspira Women's Health is a company dedicated to developing and commercializing diagnostic tests specifically for gynecologic diseases, addressing critical needs in women's health. Founded in 1993 and based in Austin, Texas, the company offers innovative testing solutions that assist healthcare providers in assessing risk and optimizing patient management. Its flagship product, OVA1 plus, combines two FDA-cleared tests to evaluate the risk of ovarian malignancy in women with adnexal masses. Additionally, Aspira's OvaSuite consists of multiple blood tests utilizing proprietary algorithms to analyze patient data, while OvaWatch is designed to assess the risk of ovarian cancer for women with pelvic masses. Aspira Women's Health aims to enhance early detection and improve treatment outcomes for women facing gynecologic health challenges.